Granulocytic sarcoma of the small intestine with CBFβ/MYH11 fusion gene: Report of an aleukaemic case and review of the literature

Leukemia Research

Volumn 27, Issue 11, 2003, Pages 1063-1066

  Xavier, Sandra G ^a,b   Fagundes, Evandro M ^c   Hassan, Rocío ^a,b   Bacchi, Carlos ^d   Conchon, Mônika ^e   Tabak, Daniel G ^a   Spector, Nelson ^b   Zalcberg, Ilana R ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^e FUNDAÇÃO PRÓ SANGUE HEMOCENTRO DE SÃO PAULO   (Brazil)

Author keywords

Aleukaemic; AML; CBF MYH11 fusion gene; Granulocytic sarcoma; Inv(16)

Indexed keywords

CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER RISK; CASE REPORT; CHROMOSOME 16; CHROMOSOME INVERSION; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; FOLLOW UP; FUSION GENE; GENE IDENTIFICATION; GRANULOCYTIC SARCOMA; HUMAN; HUMAN TISSUE; ILEUM; IMMUNOPATHOLOGY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE;

EID: 0038691846     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(03)00070-5     Document Type: Article

References (24)

1. Neiman R.S., Barcos M., Berard C., Bonner H., Mann R., Rydell R.E.et al. Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases. Cancer. 48:1981;1426-1437.
2. Hamilton M.S., Shepherd P., Porter J., Richards J.D.M. Granulocytic sarcomas of small intestine and brain are associated with acute myelomonocytic leukaemia with abnormal eosinophils and inversion of chromosome 16. Leuk Lymphoma. 8:1992;409-413.
3. Russel S.J., Giles F.J., Thompson D.S., Scanlon D.J., Walker H., Richards J.D.M. Granulocytic sarcoma of small intestine preceding acute myelomonocytic leukemia with abnormal eosinophils and inv(16). Cancer Genet Cytogenet. 35:1988;231-235.
4. Meis J.M., Butler J.J., Osborne B.M., Manning J.T. Granulocytic sarcoma in nonleukemic patients. Cancer. 58:1986;2697-2709.
5. Menasce LP, Banerjee SS, Beckett, Harris M. Extra-medullary myeloid tumour (granulocytic sarcoma) is often misdiagnosed: a study of 26 cases. Histopathology 1999;34:391-8.
6. Tallman M.S., Hakimian D., Shaw J.M., Lissner G.S., Russel E.J., Variakojis D. Granulocytic sarcoma is associated with the 8; 21 translocation in acute myeloid leukemia. J. Clin. Oncol. 11:1993;690-697.
7. Schwyzer R., Sherman G.G., Cohn R.J., Poole J.E., Willem P. Granulocytic sarcoma in children with acute myeloblastic leukemia. Med. Pediatr. Oncol. 31:1998;144-149.
8. Martinelli G., Ottaviani E., Testoni N., Visani G., Pagliani G., Tura S. Molecular analysis of granulocytic sarcoma: a single center experience. Haematologica. 84:1999;380-382.
9. Liu P.P., Hajra A., Wijmenga C., Collins F.S. Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia. Blood. 85:1995;2289-2302.
10. Van Dongen J.J.M., Macintyre E.A., Gabert J.A., Delabesse E., Rossi V., Saglio G.et al. Standardized RT-PCR analysis of fusion genes transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia. 13:1999;1901-1928.
11. Yamauchi K., Yasuda M. Comparison in treatments of nonleukemic granulocytic sarcoma - report of two cases and a review of 72 cases in the literature. Cancer. 94:2002;1739-1746.
12. Elghetany M.T. True histiocytic lymphoma: is it an entity. Leukemia. 11:1997;762-764.
13. Beswick S.J., Jones E.L., Mahendra P., Marsden J.R. Chloroma (aleukaemic leukaemia cutis) initially diagnosed as cutaneous lymphoma. Clin. Exp. Dermatol. 27:2002;272-274.
14. Larson R.A., Williams S.F., LeBeau M.M., Bitter M.A., Vardiman J.W., Rowley J.D. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) and t(16;16) has a favorable prognosis. Blood. 68:1986;1242-1249.
15. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G.et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood. 92:1998;2322-2333.
16. Holmes R., Keating M.J., Cork A., Broach Y., Trujillo J., Dalton W.T.et al. A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13;q22). Blood. 65:1985;1071-1078.
17. Drinkard L.C., Waggoner S., Stein R.N., Byrne R.A., Larson R.A. Acute myelomonocytic leukemia with abnormal eosinophils presenting as an ovarian mass: a report of two cases and a review of the literature. Gynecol. Oncol. 56:1995;307-311.
18. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 100:2002;2292-2302.
19. Slovak M.L., Kopecky K.J., Cassileth P.A., Harrington D.H., Theil K.S., Mohamed A.et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 96:2000;4075-4083.
20. Marcucci G., Caligiuri M.A., Bloomfield C.D. Defining the absence of the CBFβ/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: a call for definitions. Blood. 90:1997;5022-5025.
21. Martín G., Barragán E., Bolufer P., Chillón C., García-Sanz R., Gómez T.et al. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFβ/MYH11 rearrangement. Haematologica. 85:2000;699-703.
22. Guerrasio A., Pilatrino C., De Micheli D., Cilloni D., Serra A., Gottardi E.et al. Assessment of minimal residual disease (MRD) in CBFβ/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia. 16:2002;1176-1181.
23. Buonamici S., Ottaviani E., Testoni N., Montefusco V., Visani G., Bonifazi F.et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood. 99:2002;443-449.
24. Van der Reijden B.A., Simons A., Luiten E., Van der Poel S.C., Hogenbirk P.E., Tönnissen E.et al. Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFβ/MYH11 gene fusion. Br. J. Haematol. 118:2002;411-418.